We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

Hemostats Market: Growth, Size, Share, and Trends

Report Code MD 4093
Published in Jun, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Hemostats Market by Type (Thrombin, Combination, Gelatin, Collagen), Formulation (Matrix & Gel, Sheet & Pad, Sponge, Powder), Application (Orthopedic, General, Cardiovascular), End User (Hospital, Specialty Clinic), Region - Global Forecast to 2030

Overview

The global hemostats market, valued at US$2.80 billion in 2024, stood at US$2.90 billion in 2025 and is projected to advance at a resilient CAGR of 6.4% from 2025 to 2030, culminating in a forecasted valuation of US$4.00 billion by the end of the period. The escalation in global accident rates has led to a surge in surgical procedures characterized by extended operating durations. A significant contributor to hemorrhage in surgical and trauma cases is the suboptimal application of conventional wound closure methods, including sutures, staples, and various hemostatic agents. This inadequacy underscores the growing demand for advanced blood loss management solutions, particularly effective hemostatic products, to optimize patient outcomes during surgical interventions. In this report, the hemostats market is segmented by type, formulation, application, end user, and region.

Hemostats Market – Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Hemostats Market

Asia Pacific

The Asia Pacific market is expected to witness the highest growth during the forecast period due to a high burden of surgical procedures, healthcare infrastructure modernization, and the presence of high-growth regional markets.

Market growth is mainly driven by the growing volume of surgical procedures performed, the increasing incidence of sports-related injuries, and the rising focus on effective blood loss management in patients during surgeries.

Various companies operating in this market have made significant R&D investments to develop novel products to better cater to the needs of their customers.

The Asia Pacific hemostats market is worth USD 508.0 million in 2024, growing at the highest CAGR of 8.8% during the forecast period.

Product launches and acquisitions are the most widely adopted growth strategies by market players.

Global Hemostats Market Dynamics

DRIVER: Growing volume of surgical procedures performed

The surge in surgical interventions can be attributed to the escalating global prevalence of chronic and age-related pathologies. The geriatric population is particularly susceptible to disorders such as osteoporosis, arthritis, lumbar spinal stenosis (LSS), gastroesophageal reflux disease (GERD), and benign prostatic hyperplasia (BPH), which often necessitate surgical intervention for functional restoration or pain alleviation. Patients with arthritis and osteoporosis frequently exhibit compromised bone density and vascular integrity, rendering them more vulnerable to significant hemorrhage during procedures like joint arthroplasty or spinal surgeries. In this context, the use of hemostatic agents becomes critical for achieving rapid and reliable hemostasis, thereby mitigating the risks of hematoma formation, surgical site infections, and extended operative durations. Moreover, the rise of minimally invasive surgical techniques—which necessitate effective hemostatic management within constrained surgical environments—has further intensified the demand for advanced hemostatic products. Additionally, factors such as increased patient awareness, advancements in surgical technologies, and a stronger focus on optimized recovery protocols have collectively resulted in the broader application of hemostatic agents across various surgical disciplines.

RESTRAINT: Side effects and allergic reactions associated with hemostats

Hemostatic agents, particularly those derived from biological or animal sources, have been associated with a range of adverse effects, including fibrosis, hypersensitivity reactions, delayed wound healing, and, infrequently, surgical site infections. For example, in tendon repair procedures, absorbable gelatin-based sponges have been documented to provoke excessive fibrotic responses, potentially impairing tissue mobility. Additionally, the incomplete absorption of remaining hemostatic materials may lead to localized inflammation or disrupt the regenerative process of tissues. These negative outcomes can complicate surgical procedures, prolong recovery times, and diminish clinician confidence in specific product categories. The heightened risk of adverse effects has also prompted increased regulatory scrutiny and caution in the adoption of novel products, particularly in environments facing financial constraints. As a result, manufacturers are compelled to rigorously demonstrate the safety and biocompatibility of their products to maintain trust and facilitate broader acceptance in clinical practice.

 

OPPORTUNITY: Increasing growth opportunities in emerging economies

Emerging nations in the Asia Pacific, Latin America, and the Middle East & Africa present substantial growth opportunities for key stakeholders in the hemostats market. This trend is largely driven by advancements in healthcare infrastructure, an increasing patient demographic, and heightened healthcare spending in these regions. Additionally, the rise in disposable incomes among populations in developing countries signals broader access to healthcare services. As the middle-class segment of these populations experiences escalating medical needs, hemostat manufacturers are necessitated to develop innovative strategies to cater to this demand. Notably, these emerging markets remain relatively underpenetrated by leading players, revealing significant untapped market potential for growth and expansion.

CHALLENGES: Dearth of skilled personnel for effective use of hemostats

The effective application of hemostatic devices necessitates the involvement of trained professionals, as improper utilization—such as inadequate arterial closure—can result in persistent hemorrhage or ischemic complications. Certain hemostatic interventions require multi-step procedural techniques, underscoring the need for specialized expertise. Despite the proven efficacy of these devices in minimizing blood loss, there remains a palpable deficit of skilled surgeons and operating room staff, both in developed and developing regions. Furthermore, as hemostatic technologies and their clinical applications continue to advance rapidly, it is imperative for healthcare practitioners to continuously update their skills to ensure safe and effective use. In the absence of adequate training, even the most efficacious hemostatic agents risk underutilization or misapplication, ultimately limiting their potential benefits within the surgical environment.

Global Hemostats Market Ecosystem Analysis

The hemostats market functions within a complex and interrelated ecosystem that includes manufacturers, distributors, healthcare providers, regulatory agencies, and advocacy organizations. Manufacturers are tasked with the research, development, and innovation of hemostatic agents tailored to meet diverse surgical requirements. Distributors serve a pivotal role by ensuring that these products are readily available and efficiently delivered to hospitals and surgical centers. Healthcare providers, equipped with knowledgeable surgical teams, are the primary end users and apply these agents to effectively manage intraoperative hemorrhage. Regulatory authorities enforce rigorous standards to guarantee the safety, quality, and efficacy of hemostatic products before they enter the market. Advocacy organizations play a vital role in raising awareness, promoting clinical best practices, and providing education about bleeding control. Central to this ecosystem are patients and caregivers, whose clinical outcomes and safety concerns directly impact product adoption rates. Additionally, ongoing innovations in surgical technologies and a growing preference for minimally invasive techniques are anticipated to significantly drive market expansion.

Hemostats Market Ecosystem
 

Combination hemostats segment accounted for the highest growth rate in the hemostats market, by type, during the forecast period.

The hemostats market is bifurcated into oxidized regenerated cellulose-based hemostats, thrombin-based hemostats, combination hemostats, gelatin-based hemostats, collagen-based hemostats, and other hemostats on the basis of type. Among them, the combination hemostats segment is expected to witness the highest CAGR during the forecast period. Combination hemostats demonstrate superior efficacy in achieving hemostasis compared to single-agent products, leveraging multiple hemostatic mechanisms. For example, a formulation that integrates a gelatin matrix as a physical scaffold with thrombin, which catalyzes clot formation, facilitates rapid and reliable control of hemorrhage. By harnessing both mechanical and biochemical pathways, these agents significantly enhance hemostatic efficacy, thereby reducing surgical duration and minimizing blood loss. Additional advantages include a reduction in transfusion needs, improved wound healing outcomes, decreased postoperative complications, shorter hospital stays, and greater effectiveness in managing complex or diffuse bleeding scenarios. This multifaceted approach underscores their growing adoption in clinical settings and market proliferation.

Based on applications, the orthopedic surgery segment accounted for the largest share of the market in 2024.

The hemostats market has been segmented into orthopedic surgery, general surgery, neurological surgery, cardiovascular surgery, gynecological surgery, reconstructive surgery, and other surgical applications, based on application. Orthopedic surgery dominates the hemostats market due to the escalating prevalence of musculoskeletal disorders, particularly among the aging population. Age-related conditions such as osteoarthritis, osteoporosis, and degenerative joint diseases are becoming increasingly common, driving the demand for surgical interventions like joint arthroplasties and spinal surgeries. The growing geriatric demographic further exacerbates this trend, as older adults are more vulnerable to fractures and mobility impairments. Additionally, the rising incidence of sports-related injuries among younger individuals has significantly increased the volume of orthopedic procedures performed. These surgeries are typically associated with complex tissue management and substantial blood loss, thereby necessitating the widespread application of effective hemostatic agents to ensure safe and successful clinical outcomes. The integration of advanced hemostatic technologies is crucial in addressing these challenges and improving surgical efficacy in orthopedic practices.

North America accounted for the largest share of the hemostats market in 2024.

The hemostats market is categorized into five primary regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America is positioned as the dominant player in the hemostats sector, capturing the largest share of the market. This prevalence can be attributed to the region's robust research and development infrastructure, as well as the presence of several key industry players. These companies possess extensive expertise, substantial resources, and well-established distribution networks, all of which reinforce the region's market leadership. Furthermore, the escalating burden of chronic diseases on healthcare systems in North America serves as a significant catalyst for market expansion. This trend is further exacerbated by the increasing frequency of orthopedic, bariatric, hernia repair, cardiothoracic, and neurological surgical procedures, all of which heighten the demand for hemostatic agents.

US:FASTEST-GROWING MARKET IN REGION
NORTH AMERICA: LARGEST MARKET GLOBALLY
Hemostats Market Region

Recent Developments of Hemostats Market

  • Product launch: In April 2024, Baxter(US) launched the HEMOPATCH Sealing Hemostat, a room-temperature collagen pad approved for Hemostasis and Sealing in Europe.
  • Product approval: In November 2023, Johnson & Johnson Services, Inc. (US) announced the approval for Ethizia, an adjunctive hemostat solution that has been clinically proven to achieve sustained hemostasis in difficult-to-control bleeding situations.
  • Product approval: In August 2023, Teleflex Incorporated (US) received US FDA clearance for the expanded indication for QuikClot Control+ in cardiac surgical procedures.
  • Product launch: In July 2023, Baxter (US) launched its PERCLOT Absorbable Hemostatic Powder in the US. This will allow the company to provide surgeons with a full range of active and passive hemostatic products for bleeding control, helping to optimize care for patients.

Key Market Players

Want to explore hidden markets that can drive new revenue in Hemostats Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD Million/Billion)
Segments covered Type, Formulation, Application, End User, and Region
Geographies covered Asia Pacific, North America, Europe, Latin America, and Middle East & Africa

Frequently Asked Questions (FAQ)

Which is the fastest growing segment of the hemostats market, by formulation?

Sponges form the fastest growing segment of the hemostats market based on formulation due to their ease of use, rapid absorption, and strong hemostatic efficacy. Their compatibility with various surgical procedures and improved shelf life also drive their adoption.

What are the recent trends affecting the hemostats market?

The hemostats market is growing due to rising surgical volumes, especially in aging populations and trauma cases. Recent trends include the adoption of biodegradable and combination hemostats, minimally invasive delivery formats, and rapid expansion in emerging markets such as the Asia Pacific.

Which segments have been included in this report?

This report has the following main segments:

  • By Type
  • By Formulation
  • By Application
  • By End User
  • By Region

 

Which region is lucrative for the hemostats market?

The Asia Pacific region is expected to witness the highest CAGR in the hemostats market during the forecast period. This region comprises fast-expanding economies such as China and India, which presents promising market opportunities for hemostats.

Who are the top industry players in the global hemostats market?

The top market players in the global hemostats market are Johnson & Johnson Services, Inc. (US), Baxter (US), Pfizer Inc. (US), B. Braun SE (Germany), BD (US), Teleflex Incorporated (US), and Medtronic (Ireland).

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Hemostats Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
23
RESEARCH METHODOLOGY
28
EXECUTIVE SUMMARY
41
PREMIUM INSIGHTS
45
MARKET OVERVIEW
49
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Growing volume of surgical procedures performed
    - Increasing focus on R&D
    - Rising focus on effective blood loss management in patients during surgeries
    RESTRAINTS
    - Side effects and allergic reactions associated with hemostats
    OPPORTUNITIES
    - High growth potential in emerging economies
    - Growing number of hospitals
    CHALLENGES
    - Stringent regulatory requirements for hemostat products
    - Lack of skilled personnel for effective use of hemostats
    - High cost of hemostats
  • 5.3 INDUSTRY TRENDS
    INCREASED POPULARITY OF COMBINATION HEMOSTATS
    CONSOLIDATION OF HOSPITALS
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Passive hemostats
    - Chitosan-based hemostats
    COMPLEMENTARY TECHNOLOGIES
    - Surgical adhesives
    ADJACENT TECHNOLOGIES
    - Drug-eluting sutures for local therapeutic delivery
    - Barbed sutures
  • 5.5 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND, BY HEMOSTAT
    AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022–2024 (USD)
  • 5.6 ECOSYSTEM/MARKET MAP
  • 5.7 REIMBURSEMENT SCENARIO
  • 5.8 VALUE CHAIN ANALYSIS
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 SUPPLY CHAIN ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020–2024
    EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), 2020–2024
  • 5.12 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
    - North America
    - Europe
    - Asia Pacific
  • 5.13 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR HEMOSTATS MARKET
    JURISDICTION ANALYSIS: TOP APPLICANTS FOR PATENTS IN HEMOSTATS MARKET
  • 5.14 KEY CONFERENCES & EVENTS
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.16 ADJACENT MARKET ANALYSIS
  • 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.18 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.19 IMPACT OF ARTIFICIAL INTELLIGENCE (AI) ON HEMOSTATS MARKET
  • 5.20 CASE STUDY ANALYSIS
    EGYPT’S INCURA LEVERAGES MACHINE LEARNING TO REINVENT TRAUMA HEMOSTASIS
    SOLE-SUPPLIER TRANSITION FOR HEMOSTATIC AGENTS AT OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER
  • 5.21 INVESTMENT AND FUNDING SCENARIO
  • 5.22 IMPACT OF US TARIFF – HEMOSTATS MARKET
    INTRODUCTION
    KEY TARIFF RATES
    PRICE IMPACT ANALYSIS
    IMPACT ON REGION
    - US
    - Europe
    - Asia Pacific
    IMPACT ON END-USE INDUSTRIES
HEMOSTATS MARKET, BY TYPE
87
  • 6.1 INTRODUCTION
  • 6.2 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
    HIGH BIOCOMPATIBILITY TO DRIVE ITS ADOPTION
  • 6.3 THROMBIN-BASED HEMOSTATS
    DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT GROWTH
  • 6.4 COMBINATION HEMOSTATS
    ADVANCEMENTS IN COMBINATION MATERIALS TO DRIVE MARKET
  • 6.5 GELATIN-BASED HEMOSTATS
    HIGH ELASTICITY OFFERED BY GELATIN-BASED HEMOSTATS TO BOOST DEMAND
  • 6.6 COLLAGEN-BASED HEMOSTATS
    LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION TO PROMOTE ADOPTION OF COLLAGEN-BASED HEMOSTATS
  • 6.7 OTHER HEMOSTATS
HEMOSTATS MARKET, BY FORMULATION
99
  • 7.1 INTRODUCTION
  • 7.2 MATRIX & GEL HEMOSTATS
    ABILITY OF MATRIX & GEL HEMOSTATS TO ENHANCE PLATELET AGGREGATION TO BOOST MARKET
  • 7.3 SHEET & PAD HEMOSTATS
    ABILITY TO CUT SHEET & PAD HEMOSTATS INTO ANY SHAPE OR SIZE TO FUEL ADOPTION
  • 7.4 SPONGE HEMOSTATS
    GROWING ACCEPTANCE OF SPONGE HEMOSTATS TO DRIVE DEMAND
  • 7.5 POWDER HEMOSTATS
    ABILITY TO SPRAY POWDER FORMULATIONS DIRECTLY ON WOUNDS TO DRIVE DEMAND
HEMOSTATS MARKET, BY APPLICATION
107
  • 8.1 INTRODUCTION
  • 8.2 ORTHOPEDIC SURGERY
    INCREASING INCIDENCE OF SPORTS INJURIES TO SUPPORT MARKET GROWTH
  • 8.3 GENERAL SURGERY
    INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE GROWTH
  • 8.4 NEUROLOGICAL SURGERY
    GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET
  • 8.5 CARDIOVASCULAR SURGERY
    RISING PREVALENCE OF CVD TO DRIVE ADOPTION OF HEMOSTATS
  • 8.6 RECONSTRUCTIVE SURGERY
    GROWING NUMBER OF COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
  • 8.7 GYNECOLOGICAL SURGERY
    GROWING USE OF HEMOSTATS IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING TO SUPPORT GROWTH
  • 8.8 OTHER SURGICAL APPLICATIONS
HEMOSTATS MARKET, BY END USER
120
  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS
    GROWING ADOPTION OF MINIMALLY INVASIVE SURGERIES TO BOOST ADOPTION OF HEMOSTATS
  • 9.3 SPECIALTY CLINICS
    EXPANDING SPECIALTY CLINICS TO PROMOTE MARKET GROWTH
  • 9.4 OTHERS
HEMOSTATS MARKET, BY REGION
125
  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Strong healthcare infrastructure to support uptake of hemostats
    CANADA
    - Growing geriatric population and increasing volume of surgeries to drive demand
  • 10.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - High healthcare expenditure in Germany to drive market
    UK
    - Growing volume of hernia repair and cardiovascular surgeries to drive market
    FRANCE
    - Presence of well-established healthcare system to drive market growth
    ITALY
    - Increasing volume of surgeries to drive demand for hemostats
    SPAIN
    - Growing healthcare budget and rising efforts to boost local manufacturing of medical products to drive market
    REST OF EUROPE
  • 10.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    - Growing number of hospitals and healthcare policy reforms to drive growth
    JAPAN
    - Strong healthcare system and rising geriatric population to support market growth
    INDIA
    - Rising healthcare awareness and favorable government support to drive market
    AUSTRALIA
    - Well-established healthcare infrastructure to drive adoption of hemostats
    SOUTH KOREA
    - Growing number of cosmetic surgeries to drive demand for hemostats
    REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Brazil to dominate Latin American market for hemostats
    MEXICO
    - Low-cost surgeries to drive medical tourism in Mexico
    REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    STRENGTHENING OF HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
187
  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMOSTATS MARKET
  • 11.3 REVENUE SHARE ANALYSIS
  • 11.4 MARKET SHARE ANALYSIS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - Company footprint
    - Region footprint
    - Type footprint
    - Formulation footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs
  • 11.7 VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 R&D EXPENDITURE OF KEY PLAYERS
  • 11.10 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
206
  • 12.1 KEY PLAYERS
    JOHNSON & JOHNSON SERVICES, INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BAXTER
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    PFIZER INC.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    B. BRAUN SE
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    BECTON, DICKINSON AND COMPANY (BD)
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    TELEFLEX INCORPORATED
    - Business overview
    - Products offered
    - Recent developments
    MEDTRONIC PLC
    - Business overview
    - Products offered
    - Recent developments
    HEMOSTASIS, LLC
    - Business overview
    - Products offered
    - Recent developments
    STRYKER
    - Business overview
    - Products offered
    - Recent developments
    INTEGRA LIFESCIENCES
    - Business overview
    - Products offered
    ADVANCED MEDICAL SOLUTIONS GROUP PLC
    - Business overview
    - Products offered
    - Recent developments
    SAMYANG CORPORATION
    - Business overview
    - Products offered
  • 12.2 OTHER PLAYERS
    MARINE POLYMER TECHNOLOGIES, INC.
    GELITA MEDICAL
    DILON TECHNOLOGIES
    BETATECH MEDICAL
    MERIL LIFE SCIENCES PVT. LTD.
    BIOCER DEVELOPMENT GMBH
    UNILENE
    KATSAN MEDICAL DEVICES
    TRICOL BIOMEDICAL
    3-D MATRIX MEDICAL TECHNOLOGY
    HEMOSTAT MEDICAL GMBH
    CELOX MEDICAL LTD.
    ALTAYLAR MEDICAL
APPENDIX
254
  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORT
  • 13.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 STANDARD CURRENCY CONVERSION RATES
  • TABLE 2 RESEARCH ASSUMPTIONS
  • TABLE 3 RISK ASSESSMENT
  • TABLE 4 GERIATRIC POPULATION, BY REGION, 2016 VS. 2023
  • TABLE 5 TOTAL NUMBER OF KNEE REPLACEMENTS, 2021
  • TABLE 6 TOTAL NUMBER OF CORONARY ARTERY BYPASS GRAFT PROCEDURES, 2021
  • TABLE 7 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
  • TABLE 8 INDICATIVE PRICING FOR HEMOSTATS
  • TABLE 9 AVERAGE SELLING PRICE OF HEMOSTATS, BY REGION, 2022–2024 (USD)
  • TABLE 10 ROLE IN ECOSYSTEM: HEMOSTATS MARKET
  • TABLE 11 HEMOSTATS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 12 IMPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 13 EXPORT DATA FOR HEMOSTATS (HS CODE: 300610), BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 CLASSIFICATION OF MEDICAL DEVICES BY US FDA
  • TABLE 20 CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY IN JAPAN
  • TABLE 21 NMPA MEDICAL DEVICES CLASSIFICATION
  • TABLE 22 LIST OF MAJOR PATENTS IN HEMOSTATS MARKET 2022–2024
  • TABLE 23 HEMOSTATS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, 2025–2026
  • TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS
  • TABLE 25 KEY BUYING CRITERIA FOR END USERS
  • TABLE 26 HEMOSTATS MARKET: UNMET NEEDS
  • TABLE 27 HEMOSTATS MARKET: END-USER EXPECTATIONS
  • TABLE 28 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 29 KEY PRODUCT-RELATED TARIFFS EFFECTIVE FOR HEMOSTATS
  • TABLE 30 HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 31 MAJOR PRODUCTS IN OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET
  • TABLE 32 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 33 MAJOR PRODUCTS IN THROMBIN-BASED HEMOSTATS MARKET
  • TABLE 34 THROMBIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 35 MAJOR PRODUCTS IN COMBINATION HEMOSTATS MARKET
  • TABLE 36 COMBINATION HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 37 MAJOR PRODUCTS IN GELATIN-BASED HEMOSTATS MARKET
  • TABLE 38 GELATIN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 39 MAJOR PRODUCTS IN COLLAGEN-BASED HEMOSTATS MARKET
  • TABLE 40 COLLAGEN-BASED HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 41 OTHER HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 42 HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 43 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 44 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 45 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 46 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 47 SPONGE HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 48 SPONGE HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 49 POWDER HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 50 POWDER HEMOSTATS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS)
  • TABLE 51 HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 52 NUMBER OF KNEE & HIP REPLACEMENTS, 2021
  • TABLE 53 HEMOSTATS MARKET FOR ORTHOPEDIC SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 54 TOTAL NUMBER OF INGUINAL HERNIA REPAIR PROCEDURES, 2021
  • TABLE 55 HEMOSTATS MARKET FOR GENERAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 56 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 57 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 58 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 59 HEMOSTATS MARKET FOR GYNECOLOGICAL SURGERY, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 60 HEMOSTATS MARKET FOR OTHER SURGICAL APPLICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 61 HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 62 HEMOSTATS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 63 HEMOSTATS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 64 HEMOSTATS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 65 HEMOSTATS MARKET, BY REGION, 2023–2030 (USD MILLION)
  • TABLE 66 NORTH AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 67 NORTH AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 68 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 69 NORTH AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 71 US: KEY MACROINDICATORS
  • TABLE 72 US: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 73 US: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 74 US: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 75 US: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 76 SURGICAL PROCEDURES PERFORMED IN CANADA, 2021
  • TABLE 77 CANADA: KEY MACROINDICATORS
  • TABLE 78 CANADA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 79 CANADA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 80 CANADA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 81 CANADA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 82 EUROPE: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 83 EUROPE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 84 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 85 EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 86 EUROPE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 87 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2021
  • TABLE 88 GERMANY: KEY MACROINDICATORS
  • TABLE 89 GERMANY: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 90 GERMANY: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 91 GERMANY: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 92 GERMANY: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 93 SURGICAL PROCEDURES PERFORMED IN UK, 2021
  • TABLE 94 UK: KEY MACROINDICATORS
  • TABLE 95 UK: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 96 UK: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 97 UK: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 98 UK: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 99 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2021
  • TABLE 100 FRANCE: KEY MACROINDICATORS
  • TABLE 101 FRANCE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 102 FRANCE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 103 FRANCE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 104 FRANCE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 105 SURGICAL PROCEDURES PERFORMED IN ITALY, 2021
  • TABLE 106 ITALY: KEY MACROINDICATORS
  • TABLE 107 ITALY: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 108 ITALY: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 109 ITALY: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 110 ITALY: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 111 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2021
  • TABLE 112 SPAIN: KEY MACROINDICATORS
  • TABLE 113 SPAIN: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 114 SPAIN: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 115 SPAIN: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 116 SPAIN: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 117 REST OF EUROPE: PERCENTAGE OF GDP ON HEALTHCARE EXPENDITURE, BY COUNTRY
  • TABLE 118 REST OF EUROPE: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 119 REST OF EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 120 REST OF EUROPE: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 121 REST OF EUROPE: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 122 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 124 ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 126 ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 127 CHINA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 128 CHINA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 129 CHINA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 130 CHINA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 131 JAPAN: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 132 JAPAN: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 133 JAPAN: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 134 JAPAN: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 135 INDIA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 136 INDIA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 137 INDIA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 138 INDIA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 139 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 140 AUSTRALIA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 141 AUSTRALIA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 142 AUSTRALIA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 143 SURGICAL PROCEDURES IN SOUTH KOREA, 2021
  • TABLE 144 SOUTH KOREA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 145 SOUTH KOREA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 146 SOUTH KOREA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 147 SOUTH KOREA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 148 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 149 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 150 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 151 REST OF ASIA PACIFIC: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 152 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 153 LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 154 LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 155 LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 157 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 158 BRAZIL: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 159 BRAZIL: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 160 BRAZIL: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 161 MEXICO: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 162 MEXICO: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 163 MEXICO: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 164 MEXICO: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 165 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 166 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 167 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 168 REST OF LATIN AMERICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
  • TABLE 170 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 171 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 172 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 174 GCC COUNTRIES: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 175 GCC COUNTRIES: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 176 GCC COUNTRIES: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 177 GCC COUNTRIES: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 178 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2023–2030 (USD MILLION)
  • TABLE 179 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY FORMULATION, 2023–2030 (USD MILLION)
  • TABLE 180 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
  • TABLE 181 REST OF MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY END USER, 2023–2030 (USD MILLION)
  • TABLE 182 STRATEGIES ADOPTED BY KEY PLAYERS IN HEMOSTATS MARKET, JANUARY 2022–MAY 2025
  • TABLE 183 HEMOSTATS MARKET: DEGREE OF COMPETITION
  • TABLE 184 HEMOSTATS MARKET: REGION FOOTPRINT
  • TABLE 185 HEMOSTATS MARKET: TYPE FOOTPRINT
  • TABLE 186 HEMOSTATS MARKET: FORMULATION FOOTPRINT
  • TABLE 187 HEMOSTATS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 188 HEMOSTATS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 189 HEMOSTATS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MAY 2025
  • TABLE 190 HEMOSTATS MARKET: DEALS, JANUARY 2022–MAY 2025
  • TABLE 191 HEMOSTATS MARKET: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 192 HEMOSTATS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025
  • TABLE 193 JOHNSON & JOHNSON: COMPANY OVERVIEW
  • TABLE 194 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS OFFERED
  • TABLE 195 JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS LAUNCHES, JANUARY 2022–MAY 2025
  • TABLE 196 JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2022–MAY 2025
  • TABLE 197 JOHNSON & JOHNSON SERVICES, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025
  • TABLE 198 BAXTER: COMPANY OVERVIEW
  • TABLE 199 BAXTER: PRODUCTS OFFERED
  • TABLE 200 BAXTER: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025
  • TABLE 201 BAXTER: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025
  • TABLE 202 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 203 PFIZER INC.: PRODUCTS OFFERED
  • TABLE 204 B. BRAUN SE: COMPANY OVERVIEW
  • TABLE 205 B. BRAUN SE: PRODUCTS OFFERED
  • TABLE 206 BD: COMPANY OVERVIEW
  • TABLE 207 BD: PRODUCTS OFFERED
  • TABLE 208 BD: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025
  • TABLE 209 TELEFLEX INCORPORATED: COMPANY OVERVIEW
  • TABLE 210 TELEFLEX INCORPORATED: PRODUCTS OFFERED
  • TABLE 211 TELEFLEX INCORPORATED: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025
  • TABLE 212 TELEFLEX INCORPORATED: DEALS, JANUARY 2022–MAY 2025
  • TABLE 213 TELEFLEX INCORPORATED: OTHER DEVELOPMENTS, JANUARY 2022–MAY 2025
  • TABLE 214 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 215 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 216 MEDTRONIC: PRODUCTS APPROVALS & LAUNCHES, JANUARY 2022–MAY 2025
  • TABLE 217 MEDTRONIC: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 218 HEMOSTASIS, LLC: COMPANY OVERVIEW
  • TABLE 219 HEMOSTASIS, LLC: PRODUCTS OFFERED
  • TABLE 220 HEMOSTASIS, LLC: DEALS, JANUARY 2022–MAY 2025
  • TABLE 221 STRYKER: COMPANY OVERVIEW
  • TABLE 222 STRYKER: PRODUCTS OFFERED
  • TABLE 223 STRYKER: EXPANSIONS, JANUARY 2022–MAY 2025
  • TABLE 224 INTEGRA LIFESCIENCES: COMPANY OVERVIEW
  • TABLE 225 INTEGRA LIFESCIENCES: PRODUCTS OFFERED
  • TABLE 226 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY OVERVIEW
  • TABLE 227 ADVANCED MEDICAL SOLUTIONS GROUP PLC: PRODUCTS OFFERED
  • TABLE 228 ADVANCED MEDICAL SOLUTIONS GROUP PLC: DEALS, JANUARY 2022–MAY 2025
  • TABLE 229 SAMYANG CORPORATION: COMPANY OVERVIEW
  • TABLE 230 SAMYANG CORPORATION: PRODUCTS OFFERED
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 PRIMARY SOURCES
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY END USER, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2024)
  • FIGURE 6 REVENUE SHARE ANALYSIS FOR JHONSON & JOHNSON SERVICES, INC. (US) (2024)
  • FIGURE 7 HEMOSTATS MARKET: SUPPLY SIDE ANALYSIS (2024)
  • FIGURE 8 TOP-DOWN APPROACH
  • FIGURE 9 CAGR PROJECTIONS FROM DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES ANALYSIS (2025–2030)
  • FIGURE 10 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 HEMOSTATS MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 HEMOSTATS MARKET, BY FORMULATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 HEMOSTATS MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 HEMOSTATS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 HEMOSTATS MARKET: REGIONAL SNAPSHOT
  • FIGURE 17 GROWING NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
  • FIGURE 18 CHINA TO ACCOUNT FOR LARGEST SHARE IN ASIA PACIFIC
  • FIGURE 19 INDIA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 20 NORTH AMERICA TO DOMINATE HEMOSTATS MARKET DURING FORECAST PERIOD
  • FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGH GROWTH DURING FORECAST PERIOD
  • FIGURE 22 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN HEMOSTATS MARKET
  • FIGURE 23 HEMOSTATS MARKET: ROLE IN ECOSYSTEM, 2024
  • FIGURE 24 HEMOSTATS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 PORTER’S FIVE FORCES ANALYSIS: HEMOSTATS MARKET
  • FIGURE 26 HEMOSTATS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
  • FIGURE 28 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
  • FIGURE 29 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
  • FIGURE 30 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR HEMOSTATS MARKET (JANUARY 2014–DECEMBER 2024)
  • FIGURE 31 TOP PATENT APPLICANT COUNTRIES FOR HEMOSTATS MARKET (JANUARY 2014–DECEMBER 2024)
  • FIGURE 32 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF END USERS
  • FIGURE 33 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 34 HEMOSTATS MARKET: ADJACENT MARKETS
  • FIGURE 35 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 36 INVESTMENT/VENTURE CAPITAL SCENARIO IN HEMOSTATS MARKET, 2022–2024
  • FIGURE 37 HEMOSTATS MARKET: GEOGRAPHIC SNAPSHOT (2025–2030)
  • FIGURE 38 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 39 EUROPE: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 40 ASIA PACIFIC: HEMOSTATS MARKET SNAPSHOT
  • FIGURE 41 REVENUE SHARE ANALYSIS OF KEY PLAYERS, 2022–2024
  • FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN HEMOSTATS MARKET (2024)
  • FIGURE 43 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 44 HEMOSTATS MARKET: COMPANY FOOTPRINT
  • FIGURE 45 HEMOSTATS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 46 EV/EBITDA OF KEY VENDORS
  • FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 48 HEMOSTATS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 49 R&D EXPENDITURE OF KEY PLAYERS IN HEMOSTATS MARKET, 2022–2024
  • FIGURE 50 JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 51 BAXTER: COMPANY SNAPSHOT (2024)
  • FIGURE 52 PFIZER INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 53 B. BRAUN SE: COMPANY SNAPSHOT: (2024)
  • FIGURE 54 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 55 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2024)
  • FIGURE 56 MEDTRONIC: COMPANY SNAPSHOT (2024)
  • FIGURE 57 STRYKER: COMPANY SNAPSHOT (2024)
  • FIGURE 58 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2024)
  • FIGURE 59 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2024)
  • FIGURE 60 SAMYANG CORPORATION: COMPANY SNAPSHOT (2024)

 

The study analyzes key market dynamics, such as drivers, opportunities, restraints, challenges, and key player strategies. To track company developments such as acquisitions, product launches, expansions, agreements, and partnerships of the leading players, as well as the competitive landscape of the hemostats market, to analyze market players on various parameters within the broad categories of business and product strategy. Top-down approach was used to estimate the market size. The market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involved extensive use of various secondary sources, including directory databases like Bloomberg Business, Factiva, and D&B Hoovers, white papers, annual reports, company house documents, investor presentations, and SEC filings. This research was conducted to gather information valuable for a comprehensive, technical, market-oriented, and commercial study of the hemostats market. It also helped obtain critical insights about key players in the industry, market classification, and segmentation based on current industry trends down to the finest details. Additionally, a database of leading industry players was created through this secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

A breakdown of the primary respondents for the hemostats market is provided below:

Hemostats Market

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.

Note 2: Others include sales, marketing, and product managers.

Note 3: Companies are classified into tiers based on their total revenue. As of 2024: Tier 1=>USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The research methodology used to estimate the size of the hemostats market includes the following details.

The market sizing was undertaken from the global side.

Top-down was used to estimate and validate the hemostats market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • Primary and secondary research has determined the revenues generated by leading players operating in the hemostats market.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Hemostats Market Size: Top-down Approach

Hemostats Market

Data Triangulation

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

During surgical procedures, damage to blood vessels necessitates immediate intervention to mitigate hemorrhage—this process is referred to as hemostasis. Hemostatic agents work by facilitating the formation of fibrin clots, providing an interim solution to manage bleeding at the site. The application of hemostatic measures must be executed rapidly, precisely localized, and meticulously regulated, particularly in scenarios involving significant blood loss or in patients with congenital coagulopathies or trauma-induced vascular compromise.

Stakeholders

  • Senior Management
  • Finance Department
  • Procurement Department
  • Hospitals
  • Specialty Clinics
  • Trade Associations and Industry Bodies
  • Regulatory Bodies and Government Agencies
  • Business Research & Consulting Service Providers
  • Market Research & Consulting Firms
  • Venture Capitalists and Investors

Report Objectives

  • To define, describe, segment, analyze, and forecast the hemostats market by type, formulation, application, end user, and region
  • To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the hemostats market in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the hemostats market and comprehensively analyze their core competencies
  • To track and analyze competitive developments such as agreements, collaborations, and partnerships; expansions; acquisitions; and product launches & approvals in the hemostats market

 

Previous Versions of this Report

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) & Region - Global Forecast to 2027

Report Code MD 4093
Published in Oct, 2023, By MarketsandMarkets™

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2026

Report Code MD 4093
Published in Jul, 2021, By MarketsandMarkets™

Hemostats Market by Product (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Gynecology, Neurology, Cardiovascular, Reconstructive), Formulation (Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2023

Report Code MD 4093
Published in Sep, 2018, By MarketsandMarkets™

Hemostats Market by Product (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Gynecology, Neurology, Cardiovascular, Reconstructive), Formulation (Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2023

Report Code MD 4093
Published in Feb, 2016, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

https://www.mnmks.com/demointeractivereports/display/OGM2NDIxNzUzN2UzMDhkMWMxMGVlYmI5NjU3ODlhMzY2ODA5MWFlN2VjMTE1OTQ3MWY2NTRiOWUxN2NjNjAxNNLKAep0MiT8Dv_semdOb90VQP-SMegvY3JukHGjRHcvi68Mlp5SSJGqepS_FpWKjA,,

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Hemostats Market

DMCA.com Protection Status